Introduction
============

Chronic obstructive pulmonary disease (COPD) results from a chronic inflammatory process of the airways.[@b1-copd-8-001] The prevalence of COPD is very high, and the disease affects more than 10% of subjects aged over 40 years worldwide, and it is predicted that COPD will be the third leading cause of death by 2020.[@b2-copd-8-001] The main cause of the disease is cigarette smoking.[@b2-copd-8-001] The inflammatory process predominantly affects the small airways, is characterized by infiltration of neutrophils, macrophages, and CD8+ T cells, and leads progressively to fibrosis of the small bronchioles and destruction of the alveolar walls and lung parenchyma architecture.[@b3-copd-8-001] The functional consequences of these pathological changes are airflow limitation with air-trapping and dynamic hyperinflation, leading to reduced inspiratory capacity and increased end-expiratory lung volumes.[@b3-copd-8-001] Therefore, patients with COPD complain generally of dyspnea, particularly during exercise.[@b2-copd-8-001] This shortness of breath limits physical activity and worsens quality of life in these patients.

At present, there is no curative therapy for COPD, and the aim of treatment is to reduce symptoms and exacerbations and to improve quality of life.[@b1-copd-8-001] Treatment includes bronchodilators, rehabilitation, and home oxygen therapy. Recent studies have shown that the inhaled long-acting bronchodilators are very effective for improving symptoms, exercise capacity, and quality of life, as well as for prevention of exacerbations.[@b4-copd-8-001] The β2-agonist, indacaterol, is an ultra-long- acting bronchodilator with an established clinical efficacy and safety profile which needs to be administered only once daily.[@b5-copd-8-001],[@b6-copd-8-001] Indacaterol was approved for use in the clinic by the European Medicines Agency in 2009 and by the US Food and Drug Administration in 2011. Several clinical trials performed in patients with moderate to severe COPD have shown that indacaterol significantly improved symptoms, pulmonary function test results, and quality of life, and markedly reduced the use of rescue medication compared with a placebo control group.[@b7-copd-8-001]--[@b9-copd-8-001] Recent studies suggest that indacaterol may also improve exercise endurance in patients with COPD, but its effect on daily physical activity in these patients is not well understood as yet.[@b10-copd-8-001],[@b11-copd-8-001]

Physical activity refers to movement of the body produced by skeletal muscle contraction leading to energy expenditure.[@b12-copd-8-001] The level of physical activity during routine daily life has recently been recognized to be an important outcome parameter when evaluating the therapeutic response in patients with COPD.[@b13-copd-8-001]--[@b17-copd-8-001] Limited physical activity has been reported to be associated with more hospitalizations because of exacerbations, and markers of physical activity have been shown to predict mortality in patients with COPD.[@b18-copd-8-001]--[@b21-copd-8-001] Several studies have validated the use of accelerometers for objective measurement of physical activity in patients with the disease.[@b15-copd-8-001],[@b20-copd-8-001],[@b22-copd-8-001] In the present study, the effect of indacaterol on daily physical activity was evaluated in patients with COPD using a uniaxial accelerometer.

Materials and methods
=====================

Subjects
--------

This study included 23 patients with COPD attending the outpatient department at Matsusaka Municipal Hospital. [Table 1](#t1-copd-8-001){ref-type="table"} shows the anthropometry, clinical staging, and results of pulmonary function testing in these subjects. All of the patients were ex-smokers and not on active smoking cessation pharmacotherapy, and had stable disease with no exacerbations before the beginning or during the study. Patients who were physically unable to move and those receiving home oxygen therapy or pulmonary rehabilitation were excluded. Three patients had comorbid arterial hypertension and three had hyperuricemia. In total, 24 patients were included in the study but one was excluded because of contusions and a sprained ankle following a traffic accident. Among the 23 eligible patients, 14 were receiving tiotropium 18 μg/day (by Handihaler) while nine were receiving no therapy; thus, during the entire study period, 14 cases received treatment with tiotropium together with indacaterol and nine with indacaterol alone. None of the patients received steroids or rescue with short-acting β-agonists during the study.

The diagnosis of COPD was made according to the criteria of the American Thoracic Society.[@b1-copd-8-001] Pulmonary function tests were performed using a volume-type spirometer (Super Spiro, Discom-21FX III; Chest Corporation, Tokyo, Japan). The 6-minute walk test (6MWT) and the COPD Assessment Test (CAT) were performed based on a protocol and criteria previously described.[@b23-copd-8-001],[@b24-copd-8-001] Informed consent was obtained from all subjects before entry into the study.

Study design
------------

This was an open-label clinical trial with no randomization, no placebo group, and no blinding. To record physical activity, the patients were asked to carry a Lifecorder, a uniaxial accelerometry sensor (Suzuken Corporation, Nagoya, Japan),[@b25-copd-8-001] fixed to their belts for 4 weeks without receiving indacaterol therapy and then for another period of 4 weeks while receiving 150 μg of inhaled indacaterol ([Figure 1](#f1-copd-8-001){ref-type="fig"}). Physical activity before and after treatment with indacaterol was then compared. Before the trial was started, there was a period of adaptation during which each patient received instructions on how to fix and use the device correctly. Patients were instructed to fix the device every day upon waking and to remove it before going to sleep.

Statistical analysis
--------------------

All data are expressed as the mean ± standard error of the mean. The difference between the means of two variables was assessed using the nonparametric Wilcoxon's rank test. Statistical analyses were performed using the StatView 4.5 package for Macintosh (Abacus Concepts, Berkeley, CA). A *P* value less than 0.05 was considered to be statistically significant.

Results
=======

Pulmonary function, 6MWT, and CAT
---------------------------------

Forced expiratory volume in one second (FEV~1~) and 6MWT are important parameters when assessing the response to therapy in patients with COPD.[@b1-copd-8-001] Comparing these parameters before and after treatment showed a significant increase in FEV~1~ and in maximum inspiratory capacity after 4 weeks of treatment with indacaterol ([Figure 2A and B](#f2-copd-8-001){ref-type="fig"}). Similarly, the distance walked during the 6MWT was significantly increased after treatment compared with that before starting indacaterol ([Figure 2C](#f2-copd-8-001){ref-type="fig"}). The CAT score also tended to decrease after treatment with indacaterol but this did not reach a statistically significant level ([Figure 2D](#f2-copd-8-001){ref-type="fig"}).

Physical activity parameters
----------------------------

The Lifecorder was carried by all patients, and the number of steps, duration of moderate or higher degree exercise, energy expenditure, and metabolic equivalent of task were measured. The number of steps ([Figure 3A](#f3-copd-8-001){ref-type="fig"}), time in seconds of moderate or more activity ([Figure 3B](#f3-copd-8-001){ref-type="fig"}), and energy expenditure expressed in kilocalories ([Figure 3C](#f3-copd-8-001){ref-type="fig"}) were significantly increased after treatment compared with baseline in all patients. The metabolic equivalent of task was also significantly improved after treatment with indacaterol compared with baseline data ([Figure 3D](#f3-copd-8-001){ref-type="fig"}).

Discussion
==========

The results of this study show that the long-acting β2-agonist, indacaterol, significantly and effectively improved daily physical activity in patients with COPD and that the physical activity parameters recorded using the uniaxial accelerometry sensor are useful for monitoring the therapeutic response in this group of patients.

The mainstay of treatment for symptomatic improvement in patients with COPD is inhaled bronchodilators.[@b1-copd-8-001] Of these, the ultra-long-acting β2-adrenoreceptor agonist, indacaterol, and the long-acting antimuscarinic, tiotropium bromide, have been shown to be very effective for reducing symptoms, to increase exercise tolerance, to reduce the frequency of exacerbations, and to improve quality of life test scores.[@b4-copd-8-001] These drugs have a further advantage over previous long-acting bronchodilators, in that they can be used once daily, so are associated with fewer side effects.[@b4-copd-8-001],[@b26-copd-8-001],[@b27-copd-8-001] In the present study, we focused on the β2-agonist, indacaterol, and evaluated whether it can improve exercise capacity and FEV~1~ in patients with COPD treated for 4 weeks, and our results showed that this agent significantly improved the results of lung function testing and exercise endurance as measured by the 6MWT.

One hurdle that needs to be overcome in the management of patients with COPD is the assessment of response to therapy in terms of physical activity during routine daily life. Recent studies have validated the use of several accelerometers in the assessment of the level of activity in COPD patients.[@b15-copd-8-001],[@b21-copd-8-001] The results reported have shown a significant association between a low level of physical activity as measured by accelerometers and increased mortality and morbidity from COPD.[@b21-copd-8-001] In addition, less active patients are more likely to be hospitalized as a result of exacerbations.[@b20-copd-8-001] To the authors' knowledge, the efficacy of indacaterol in daily life activity has not been evaluated until now. In the present study, we used a novel accelerometer, the sensitivity and efficacy of which has been previously validated.[@b25-copd-8-001] This novel accelerometer can measure several indicators of daily physical activity, including the number of steps, energy expenditure, and metabolic equivalent of task.[@b25-copd-8-001] The device is easy to use, cost-effective, and can record data on a real-time basis every 4 seconds and over a lengthy period of time. We carried out a prospective and open clinical trial to assess whether indacaterol can improve daily physical activity in patients with COPD. The number of steps, energy expenditure, and metabolic equivalent of task were significantly increased in all patients after treatment with indacaterol, suggesting that this β2-agonist improves routine daily activity in patients with COPD.

Our study has several limitations, including its open nature, a small patient population, lack of a placebo control group, and no randomization. In addition, although the patients were-not asked or motivated to perform any exercise other than their normal or routine daily physical activity, they knew that they were receiving the drug during the second period of the study and therefore they could have been psychologically motivated or encouraged to perform better during their daily physical activity. However, to avoid some of these confounding factors, the patients were allowed to have an adaptation period during which they received training about how to use the device and about the performance of lung function tests.

In brief, this study provides early evidence that indacaterol improves daily activity in patients with COPD. However, a larger patient population and a placebo control group should be included in future studies to validate the present findings.
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![Study design.\
**Notes:** Patients fixed the Lifecorder to their belts for a period of 4 weeks without receiving indacaterol therapy and then for another period of 4 weeks while receiving 150 μg of inhaled indacaterol.](copd-8-001f1){#f1-copd-8-001}

![Response to indacaterol. Maximum inspiratory capacity (**A**), FEV~1~ (**B**), and 6MWT (**C**) improved significantly after 4 weeks of treatment with indacaterol. The CAT score (**D**) tended to decrease after treatment with indacaterol.\
**Notes:** Horizontal bars indicate the means. Statistical analysis was performed using the nonparametric Wilcoxon's rank test.\
**Abbreviations:** 6MWT, six-minute walk test; CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in one second.](copd-8-001f2){#f2-copd-8-001}

![Effect of indacaterol on physical activity parameters. Number of steps (**A**), duration of moderate or more exercise (**B**), energy expenditure (**C**) and metabolic equivalent of task (**D**) improved significantly after treatment with indacaterol in all patients.\
**Notes:** Horizontal bars indicate the means. Statistical analysis was performed using the nonparametric Wilcoxon's rank test.](copd-8-001f3){#f3-copd-8-001}

###### 

Baseline demographic data for patients with chronic obstructive pulmonary disease

  ---------------------------------- ---------------
  Patients (n)                       23
  Age (years)                        69.74 ± 1.60
  Gender (M/F)                       21/2
  Body mass index                    21.59 ± 0.72
  GOLD scale (patients, n)           
   1                                 6
   2                                 10
   3                                 6
   4                                 1
  Maximum inspiratory capacity (L)   2.06 ± 0.088
  Forced vital capacity (L)          3.319 ± 0.101
  FEV~1~ (% predicted)               64.5 ± 4.3
  ---------------------------------- ---------------

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume in one second.
